Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial

被引：20

作者：

Jacobus, Susanna J.

Cohen, Adam D.

Weiss, Matthias

Callander, Natalie Scott

Singh, Avina A.

Parker, Terri L.

Menter, Alex R.

Yang, Xuezhong

Parsons, Benjamin Marshall

Kumar, Pankaj

Kapoor, Prashant

Rosenberg, Aaron Seth

Zonder, Jeffrey A.

Faber, Edward Anthony

Lonial, Sagar

Richardson, Paul G.

Orlowski, Robert Z.

Wagner, Lynne I.

Rajkumar, S. Vincent

机构：

[1] Mayo Clin, Rochester, MN USA

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[4] ThedaCare, Appleton, WI USA

[5] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[6] MOHPA, Burnsville, MN USA

[7] Yale Univ, Hamden, CT USA

[8] Kaiser Permanente Lone Tree, Lone Tree, CO USA

[9] St Francis Canc Ctr, Greenville, NC USA

[10] Gundersen Hlth Syst, La Crosse, WI USA

[11] Illinois CancerCare, Peoria, IL USA

[12] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA 95817 USA

[13] Wayne State Univ, Sch Med, Dept Malignant Hematol, Barbara Ann Karmanos Canc Inst, Detroit, MI USA

[14] Oncol Hematol Care Inc, Cincinnati, OH USA

[15] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[16] Dana Farber Canc Inst, Boston, MA 02115 USA

[17] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[18] Wake Forest Univ Hlth Sci, Winston Salem, NC USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 18期

基金：

美国国家卫生研究院;

关键词：

283-224-288-3564261-492-27693223553611458764;

D O I：

10.1200/JCO.2020.38.18_suppl.LBA3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA3

引用

页数：3